GC Genome

GC Genome FCF Yield

The Free Cash Flow Yield of GC Genome (340450.KQ) as of Oct 19, 2026 is 0.50 %. In the previous year, Free Cash Flow Yield was -0.02 % — a change of -2,599.41% (higher).

FCF Yield

0.50 %

YoY

-2,599.41%

Last updated:

Free Cash Flow Yield of GC Genome is 2025 0.50 % . Free Cash Flow Yield of GC Genome was 2024 -0.02 % . It decreases by -2,599.41% higher compared to the previous year.

The GC Genome FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2022
-3.04 KRW
Jan 1, 2023
-2.20 KRW
Jan 1, 2024
-0.02 KRW
Jan 1, 2025
0.50 KRW
The GC Genome FCF Yield history
YEARFCF YieldYoY
0.50 %-2,599.41%
-0.02 %-99.08%
-2.20 %-27.56%
-3.04 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GC Genome Stock analysis

What does GC Genome do? GC Genome Corp is a biotechnology company based in Yongin, South Korea, operating within the healthcare sector. The company specializes in clinical genome analysis, focusing on genetic testing services for various medical applications. GC Genome Corp provides prenatal and newborn screening, cancer patient precision diagnosis, and genetic testing for rare diseases. It also offers health checkup test services. The company has 125 full-time employees and completed its initial public offering (IPO) on June 11, 2025. Its headquarters are located in Yongin, Gyeonggi-Do. The company's website is https://www.gcgenome.com/. GC Genome Corp is engaged in the development and delivery of genetic testing solutions tailored to specific healthcare needs, emphasizing precision diagnostics in clinical settings. The firm's services are designed to support medical professionals in making informed decisions regarding patient care through advanced genomic analysis. The company operates in a specialized segment of the biotechnology industry, targeting both clinical and preventive healthcare markets. GC Genome Corp's business model centers on providing accurate and reliable genetic testing services to healthcare providers and patients seeking personalized medical insights. The company's IPO date marks its transition to a publicly traded entity, reflecting its growth and market positioning within the healthcare technology sector. GC Genome is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GC Genome stock

Free Cash Flow Yield of GC Genome is 0.50 % in 2025.

Free Cash Flow Yield of GC Genome changed from -0.02 % to 0.50 %, representing a -2,599.41% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield GC Genome since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's GC Genome with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — GC Genome

All Key Metrics — GC Genome